Johnson & Johnson (JNJ)
Johnson & Johnson is an American multinational corporation that operates in the healthcare, consumer goods, and pharmaceutical industries. It is known for its consumer products, such as Band-Aid and Tylenol, as well as its pharmaceutical products and medical devices. Johnson & Johnson has a strong presence in the global market and is headquartered in New Brunswick, New Jersey.
Company Info
US4781601046
478160104
Sep 24, 1944
Highlights
$371.06B
$8.99
17.15
1.05
$89.33B
$61.01B
$34.70B
$139.56 - $169.99
$169.98
0.82%
1.74
Share Price Chart
Loading data...
Compare to other instruments
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
Loading data...
Returns By Period
Johnson & Johnson (JNJ) returned 7.49% year-to-date (YTD) and 6.18% over the past 12 months. Over the past 10 years, JNJ returned 7.19% annually, underperforming the S&P 500 benchmark at 10.70%.
JNJ
7.49%
1.64%
0.79%
6.18%
3.83%
7.19%
^GSPC (Benchmark)
-0.64%
8.97%
-2.52%
11.90%
15.34%
10.70%
Monthly Returns
The table below presents the monthly returns of JNJ, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | 5.21% | 9.33% | 0.50% | -5.75% | -1.34% | 7.49% | |||||||
| 2024 | 1.38% | 2.33% | -1.98% | -8.60% | 2.26% | -0.35% | 8.00% | 5.87% | -2.29% | -1.36% | -2.26% | -6.70% | -4.81% |
| 2023 | -7.49% | -5.54% | 1.14% | 5.61% | -4.56% | 6.75% | 1.21% | -2.79% | -3.67% | -4.76% | 5.10% | 1.34% | -8.58% |
| 2022 | 0.71% | -3.87% | 7.69% | 1.82% | 0.12% | -1.13% | -1.68% | -6.93% | 1.25% | 6.49% | 2.98% | -0.76% | 5.97% |
| 2021 | 3.65% | -2.26% | 3.72% | -0.99% | 4.66% | -2.66% | 4.53% | 1.14% | -6.72% | 0.85% | -3.64% | 9.71% | 11.44% |
| 2020 | 2.06% | -9.09% | -2.49% | 14.42% | -0.17% | -5.46% | 3.65% | 5.95% | -2.95% | -7.91% | 6.25% | 8.78% | 10.82% |
| 2019 | 3.12% | 3.36% | 2.31% | 1.01% | -6.48% | 6.20% | -6.50% | -0.69% | 0.79% | 2.06% | 4.85% | 6.09% | 16.22% |
| 2018 | -1.10% | -5.41% | -1.33% | -1.30% | -4.73% | 1.44% | 9.21% | 2.31% | 2.58% | 1.32% | 5.60% | -12.15% | -5.13% |
| 2017 | -1.70% | 8.63% | 1.91% | -0.87% | 4.56% | 3.15% | 0.33% | 0.37% | -1.78% | 7.23% | 0.55% | 0.28% | 24.43% |
| 2016 | 1.67% | 1.47% | 2.84% | 3.59% | 1.26% | 7.64% | 3.24% | -4.07% | -1.01% | -1.81% | -3.38% | 3.51% | 15.33% |
| 2015 | -4.24% | 3.08% | -1.86% | -1.39% | 1.68% | -2.68% | 2.82% | -5.50% | -0.67% | 8.23% | 0.95% | 1.46% | 1.14% |
| 2014 | -3.41% | 4.87% | 6.63% | 3.12% | 0.87% | 3.11% | -4.33% | 4.34% | 2.76% | 1.12% | 1.09% | -3.40% | 17.34% |
Risk-Adjusted Performance
Risk-Adjusted Performance Rank
The current rank of JNJ is 63, indicating average performance compared to other stocks on our website. Here’s a breakdown of how it compares using common performance measures.
Risk-Adjusted Performance Indicators
The charts below present risk-adjusted performance metrics for Johnson & Johnson (JNJ) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.
Loading data...
Dividends
Dividend History
Johnson & Johnson provided a 3.22% dividend yield over the last twelve months, with an annual payout of $4.96 per share. The company has been increasing its dividends for 27 consecutive years, earning it the status of a dividend aristocrat.
| Period | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend | $4.96 | $4.91 | $4.70 | $4.45 | $4.19 | $3.98 | $3.75 | $3.54 | $3.32 | $3.15 | $2.95 | $2.76 |
Dividend yield | 3.22% | 3.40% | 3.00% | 2.52% | 2.45% | 2.53% | 2.57% | 2.74% | 2.38% | 2.73% | 2.87% | 2.64% |
Monthly Dividends
The table displays the monthly dividend distributions for Johnson & Johnson. The dividends shown in the table have been adjusted to account for any splits that may have occurred.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | $0.00 | $1.24 | $0.00 | $0.00 | $0.00 | $1.24 | |||||||
| 2024 | $0.00 | $1.19 | $0.00 | $0.00 | $1.24 | $0.00 | $0.00 | $1.24 | $0.00 | $0.00 | $1.24 | $0.00 | $4.91 |
| 2023 | $0.00 | $1.13 | $0.00 | $0.00 | $1.19 | $0.00 | $0.00 | $1.19 | $0.00 | $0.00 | $1.19 | $0.00 | $4.70 |
| 2022 | $0.00 | $1.06 | $0.00 | $0.00 | $1.13 | $0.00 | $0.00 | $1.13 | $0.00 | $0.00 | $1.13 | $0.00 | $4.45 |
| 2021 | $0.00 | $1.01 | $0.00 | $0.00 | $1.06 | $0.00 | $0.00 | $1.06 | $0.00 | $0.00 | $1.06 | $0.00 | $4.19 |
| 2020 | $0.00 | $0.95 | $0.00 | $0.00 | $1.01 | $0.00 | $0.00 | $1.01 | $0.00 | $0.00 | $1.01 | $0.00 | $3.98 |
| 2019 | $0.00 | $0.90 | $0.00 | $0.00 | $0.95 | $0.00 | $0.00 | $0.95 | $0.00 | $0.00 | $0.95 | $0.00 | $3.75 |
| 2018 | $0.00 | $0.84 | $0.00 | $0.00 | $0.90 | $0.00 | $0.00 | $0.90 | $0.00 | $0.00 | $0.90 | $0.00 | $3.54 |
| 2017 | $0.00 | $0.80 | $0.00 | $0.00 | $0.84 | $0.00 | $0.00 | $0.84 | $0.00 | $0.00 | $0.84 | $0.00 | $3.32 |
| 2016 | $0.00 | $0.75 | $0.00 | $0.00 | $0.80 | $0.00 | $0.00 | $0.80 | $0.00 | $0.00 | $0.80 | $0.00 | $3.15 |
| 2015 | $0.00 | $0.70 | $0.00 | $0.00 | $0.75 | $0.00 | $0.00 | $0.75 | $0.00 | $0.00 | $0.75 | $0.00 | $2.95 |
| 2014 | $0.66 | $0.00 | $0.00 | $0.70 | $0.00 | $0.00 | $0.70 | $0.00 | $0.00 | $0.70 | $0.00 | $2.76 |
Dividend Yield & Payout
Dividend Yield
Johnson & Johnson has a dividend yield of 3.22%, which is quite average when compared to the overall market.
Payout Ratio
Johnson & Johnson has a payout ratio of 49.95%, which is quite average when compared to the overall market. This suggests that Johnson & Johnson strikes a balance between reinvesting profits for growth and paying dividends to shareholders.
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading data...
Worst Drawdowns
The table below displays the maximum drawdowns of the Johnson & Johnson. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Johnson & Johnson was 52.60%, occurring on Apr 25, 1977. Recovery took 1348 trading sessions.
The current Johnson & Johnson drawdown is 9.41%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -52.6% | Nov 2, 1972 | 1128 | Apr 25, 1977 | 1348 | Aug 25, 1982 | 2476 |
| -44.75% | Jan 5, 1983 | 393 | Jul 24, 1984 | 351 | Dec 12, 1985 | 744 |
| -43.02% | Feb 8, 1962 | 179 | Oct 23, 1962 | 246 | Oct 15, 1963 | 425 |
| -38.78% | Jan 9, 1992 | 403 | Aug 11, 1993 | 399 | Mar 10, 1995 | 802 |
| -38.35% | Aug 26, 1987 | 38 | Oct 19, 1987 | 415 | Jun 9, 1989 | 453 |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading data...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Johnson & Johnson over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Earnings Per Share
The chart presents the Earnings Per Share (EPS) performance of Johnson & Johnson, comparing actual results with analytics estimates. The company has exceeded analyst expectations for EPS in the past quarter, achieving a 6.9% positive surprise.
Valuation
The Valuation section provides an overview of how Johnson & Johnson is priced in the market compared to other companies in the Drug Manufacturers - General industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PE Ratio
The chart displays the Price-to-Earnings (P/E) ratio for JNJ, comparing it with other companies in the Drug Manufacturers - General industry. Currently, JNJ has a P/E ratio of 17.2. This P/E ratio is considered low compared to industry peers, which may suggest that the stock is undervalued or that the company has weaker growth prospects.
PEG Ratio
The chart shows the Price/Earnings to Growth (PEG) ratio for JNJ compared to other companies in the Drug Manufacturers - General industry. JNJ currently has a PEG ratio of 1.0. This PEG ratio is close to the industry average, suggesting the stock’s valuation is balanced against its growth outlook.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for JNJ relative to other companies in the Drug Manufacturers - General industry. Currently, JNJ has a P/S ratio of 4.2. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for JNJ in comparison with other companies in the Drug Manufacturers - General industry. Currently, JNJ has a P/B value of 4.8. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |